Clinical Trials


Tenofovir to Prevent HBV Reactivation

This study is currently recruiting participants. (see Contacts and Locations)

Verified October 2017 by University Health Network, Toronto

University Health Network, Toronto

Information provided by (Responsible Party)
University Health Network, Toronto Identifier

First received: July 7, 2014
Last updated: October 30, 2017
Last Verified: October 2017
History of Changes


The purpose of the study is to determine how effective preemptive tenofovir therapy is in preventing the re-activation of Hepatitis B infection, in patients who are receiving rituximab-based chemotherapy for Non-Hodgkin's Lymphoma or CLL/SLL. The rate of re-activation will be compared between patients who receive preemptive tenofovir and patients who receive tenofovir as needed.

Condition Intervention Phase
Hepatitis B

Drug : Tenofovir disoproxil
Drug : Placebo Oral Tablet
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-centre Phase III Study to Evaluate Pre-emptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Anti-CD20-based Chemotherapy for Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Further study details as provided by University Health Network, Toronto:

Primary Outcome Measures

  • Rate of reverse seroconversion [ Time Frame: 12 months post-chemotherapy ]
    The difference in the rate of reverse seroconversion or Hepatitis B (HBV)-associated hepatitis (definition: appearance of HBsAg in the serum with or without detectable HBV DNA in a patient who was previously HBsAg-/cAb+.) between the intervention and placebo groups.
Secondary Outcome Measures:
  • Rates of HBV Reactivation [ Time Frame: 12 months post-chemotherapy ]
  • Severe HBV-associated hepatitis [ Time Frame: 12 months post-chemotherapy ]
  • HBV-related liver failure [ Time Frame: 12 months post-chemotherapy ]
  • Liver-related death [ Time Frame: 12 months post-chemotherapy ]
  • Treatment-related adverse effects (AEs) [ Time Frame: 12 months post-chemotherapy ]
  • Time to start chemotherapy [ Time Frame: 12 months post-chemotherapy ]
  • Chemotherapy interruption [ Time Frame: 12 months post-chemotherapy ]
  • All-cause mortality [ Time Frame: 12 months post-chemotherapy ]

Estimated Enrollment: 184
Study Start Date: May 2015
Estimated Study Completion Date: June 2020
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Active Comparator: Pre-emptive tenofovir
Tenofovir disoproxil
Drug: Tenofovir disoproxil
Other Name: Viread
Placebo Comparator: Placebo
Drug: Placebo Oral Tablet
Other Name: Placebo


Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria:

    1. ≥ 18 years of age
    2. Diagnosis of non-Hodgkin's lymphoma to be treated with rituximab-based chemotherapy
    3. HBsAg negative, anti-HBc positive

Exclusion Criteria:
    1. Current therapy with known activity against HBV
    2. Screening ALT > 10 x ULN
    3. Screening ALT >2 and <10 xULN with HBV DNA > 2000 IU/mL (indicates active HBV infection despite HBsAg negative and require antiviral therapy)
    4. Life expectancy < 3 months
    5. HBsAg positive
    6. HIV co-infection
    7. Active HCV co-infection (HCV RNA positive)
    8. Creatinine clearance <50 mL/min
    9. Intolerance to tenofovir
    10. Women of child-bearing potential unwilling to take contraception during the study

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02186574


Contact:   Jordan Feld, MD 416-340-4584
Contact:   Jamuna Nanthakumar, CCRP 416-340-4800 ext 6453


Toronto General Hospital Active, not recruiting
Toronto, Ontario, Canada, M5G 2C4
Princess Margaret Cancer Centre Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Nimisha Dave, BSc    416-946-4501 ext 4753
Contact: Ruth Turner, RN    416-946-2987
Principal Investigator: Michael Crump, MD

Sponsors and Collaborators

University Health Network, Toronto


Study Director: Harry Janssen, MD University Health Network, Toronto
More Information

More Information

Responsible Party: University Health Network, Toronto Identifier: NCT02186574   History of Changes  
Other Study ID Numbers: JF62014  
Study First Received: July 7, 2014  
Last Updated: October 30, 2017  

Keywords provided by University Health Network, Toronto:

Hepatitis B

Additional relevant MeSH terms:
Hepatitis A
Hepatitis B
Tenofovir processed this data on September 24, 2018
This information is provided by